Manuel Bruno-Fernandez - Publications

Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016-2025).

Journal: Archivos de bronconeumologia

Published: January 13, 2026

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia.

Journal: Frontiers in oncology

Published: August 01, 2025

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Journal: Nature communications

Published: May 23, 2025

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain.

Journal: The Lancet regional health. Europe

Published: April 10, 2025

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 06, 2025

Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry.

Journal: Archivos de bronconeumologia

Published: May 28, 2024

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.

Journal: Cancers

Published: July 02, 2019

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Journal: OncoTargets and therapy

Published: March 05, 2019

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Journal: Translational lung cancer research

Published: December 04, 2018

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Journal: Translational lung cancer research

Published: November 06, 2018

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).

Journal: EBioMedicine

Published: November 05, 2018

EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Journal: Translational cancer research

Published: August 27, 2018